AbbVie Inc. (ABBV)
Estimates & Forecasts•Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
ABBV Price Targets Summary| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Net Income | $4.9B | $4.3B | $4.2B | $13.6B | $13.3B | $5.6B | $6.0B |
| EPS (Diluted) | $2.72 | $2.39 | $2.37 | $7.66 | $7.52 | $3.15 | $3.37 |
| YoY Growth | — | -12.0% | -1.2% | +220.7% | -1.8% | -58.0% | +7.0% |
| Net Margin | 9.0% | 7.6% | 6.9% | 20.6% | 19.0% | 7.7% | 7.9% |
USD · ABBV · Proprietary Model| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $61.2B | $65.8B | $70.1B | $72.3B | $75.9B |
| Net Income | $4.2B | $13.6B | $13.3B | $5.6B | $6.0B |
| EPS (Diluted) | $2.37 | $7.66 | $7.52 | $3.15 | $3.37 |
| Free Cash Flow | $17.8B | $9.6B | $10.5B | $11.2B | $12.0B |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
Quick answers to the most common questions about buying ABBV stock.
AbbVie Inc.'s projected EPS for the next fiscal year is $7.66. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 54/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for AbbVie Inc.: Bear case $222, Base case $654, and Bull case $793. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
AbbVie Inc.'s projected revenue growth for the next fiscal year is 7.7%, reaching approximately $65.8B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 54/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Contracting margins add uncertainty to forward projections. No forecast model is perfect — always cross-reference with your own analysis.
AbbVie Inc.'s forward operating margin is estimated at 26.6% for the next fiscal year. The margin trend is currently "contracting". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($222) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is below Wall Street consensus with a 46.0% gap. For FY+1, analyst estimates blend with our model at 43% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.